2 results
Approved WMOCompleted
The main objective of Study M15-722 is to characterize the efficacy, safety, and tolerability of ravagalimab (ABBV-323) as induction treatment in subjects with moderately to severely active UC.
Approved WMORecruiting
The main objective is the %TBWL 5 years after surgery. Secondary objectives include Percentage Excess Weight Loss (%EWL); decrease of comorbidities such as diabetes mellitus (DM), hypertension, and hypercholesterolemia; improvement of quality of…